

Alerts and Recalls

Generic Name (Trade Name—Company)

June 2, 2018

Follitropin alfa injection

(Gonal-f RFF Redi-ject, Gonal-f Multi-Dose—EMD Serono)

FDA warns of stolen fertility drugs

Uses/Notes

FDA is alerting health professionals, patients, and the drug supply chain of [stolen injectable fertility medications](#) Gonal-f RFF Redi-ject, Gonal-f Multi-Dose (follitropin alfa injection). Patients who have product with these [lot numbers](#) should not use them.

All product with these lot numbers were in this stolen shipment. The lot numbers are located on the flap of each box, below the tamper-proof seal and next to the 2D barcode.

The products were stolen in Italy on May 17, 2018, and were intended to be shipped to the United States. EMD Serono of Rockland, MA, reported the theft of more than 16,000 packages of follitropin alfa injection to FDA on May 18, 2018.

Drug supply chain stakeholders that receive or possess these lot numbers must [notify](#) FDA via [Form FDA 3911](#). Anyone who has received suspicious or unsolicited offers to purchase follitropin alfa injection products since May 17, 2018, should contact [FDA Office of Criminal Investigations](#) at 800-551-3989.

Drug supply chain stakeholders should continue to remain vigilant when buying or selling these products and check the lot number to prevent stolen product from entering the drug supply chain.

Patients, health professionals, and drug supply chain stakeholders should check the product and label for signs of tampering before using.

FDA also reminds health professionals, patients, and drug supply chain stakeholders to purchase products only from licensed wholesale distributors and pharmacies. See FDA's [Know Your Source](#) and [BeSafeRx](#) programs for more information.

Source URL:

<http://personify.pharmacist.com/alerts-and-recalls/fda-warns-stolen-fertility-drugs>

APhA DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in APhA DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.